Shares of Biogen (BIIB) are down $5.42, or 2%, to $226.35 in afternoon trading after Eli Lilly (LLY) announced that the Food and Drug Administration approved Kisunla for adults with early symptomatic Alzheimer’s disease, or AD, which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology. “Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions,” Eli Lilly stated. In afternoon trading, Eli Lilly shares are down about 1% to $906.28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Completes Acquisition of Human Immunology Biosciences
- Biogen’s Lecanemab launched in China to treat Alzheimer’s Disease
- Biogen’s Lecanemab launched in China to treat Alzheimer’s Disease Use symbol Eisai
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
- RBC believes Leqembi on track for EU approval after speaking to Biogen